{"news_desk": "Business", "print_page": "2", "section_name": "Business Day", "subsection_name": null, "byline": {"original": "By KATIE THOMAS", "person": [{"rank": 1, "role": "reported", "firstname": "Katie", "organization": "", "lastname": "THOMAS"}]}, "abstract": "Valeant Pharmaceuticals announces former chief executive J Michael Pearson will receive $9 million severance payment and will continue on in capacity of consultant until end of 2017; Pearson left company due to number of investigations into company's business practices.", "type_of_material": "News", "word_count": "340", "lead_paragraph": "J. Michael Pearson stepped down amid a series of investigations into Valeant\u2019s business practices.", "pub_date": "2016-06-01T00:00:00Z", "document_type": "article", "slideshow_credits": null, "headline": {"main": "Valeant\u2019s Former C.E.O. to Receive $9 Million Severance", "print_headline": "Valeant\u2019s Ex-Chief Is Given $9 Million in Severance Pay"}, "snippet": "J. Michael Pearson stepped down amid a series of investigations into Valeant\u2019s business practices.", "multimedia": [{"height": 126, "url": "images/2016/06/01/business/01valeant/01valeant-thumbWide.jpg", "legacy": {"widewidth": "190", "wideheight": "126", "wide": "images/2016/06/01/business/01valeant/01valeant-thumbWide.jpg"}, "type": "image", "width": 190, "subtype": "wide"}, {"height": 400, "url": "images/2016/06/01/business/01valeant/01valeant-articleLarge.jpg", "legacy": {"xlargewidth": "600", "xlargeheight": "400", "xlarge": "images/2016/06/01/business/01valeant/01valeant-articleLarge.jpg"}, "type": "image", "width": 600, "subtype": "xlarge"}, {"height": 75, "url": "images/2016/06/01/business/01valeant/01valeant-thumbStandard.jpg", "legacy": {"thumbnailwidth": "75", "thumbnail": "images/2016/06/01/business/01valeant/01valeant-thumbStandard.jpg", "thumbnailheight": "75"}, "type": "image", "width": 75, "subtype": "thumbnail"}], "web_url": "http://www.nytimes.com/2016/06/01/business/c-michael-pearson-former-valeant-chief-to-receive-9-million-severance.html", "keywords": [{"rank": "1", "is_major": "Y", "value": "Valeant Pharmaceuticals International Inc", "name": "organizations"}, {"rank": "2", "is_major": "Y", "value": "Executive Compensation", "name": "subject"}, {"rank": "3", "is_major": "Y", "value": "Pearson, John Michael (1959- )", "name": "persons"}, {"rank": "4", "is_major": "N", "value": "Securities and Exchange Commission", "name": "organizations"}, {"rank": "5", "is_major": "N", "value": "Mergers, Acquisitions and Divestitures", "name": "subject"}], "blog": [], "_id": "574db35738f0d826276783fa", "source": "The New York Times"}